Ryan S Chiang1, Ashton A Connor2, Brant A Inman3, Wen-Chi Foo4, David N Howell4, John F Madden4, Matthew J Ellis5, Aparna S Rege2, Michael R Harrison6. 1. Department of Medicine, Stanford University Medical Center, Stanford, CA, USA. 2. Division of Abdominal Transplant Surgery, Department of Surgery, Duke University School of Medicine, Durham, NC, USA. 3. Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA. 4. Department of Pathology, Duke University School of Medicine, Durham, NC, USA. 5. Divisions of Nephrology and Abdominal Transplant, Departments of Medicine and Surgery, Duke University School of Medicine, Durham, NC, USA. 6. Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Abstract
BACKGROUND: Donor-derived malignancy is a rare complication in patients who undergo organ transplant. Approaches to treatment have largely been individualized based on clinical circumstances given the lack of evidence-based guidelines, with therapeutic options ranging from discontinuation of immunosuppression and transplantectomy to the addition of chemotherapy or radiotherapy. Case Presentation. Herein, we describe a 60-year-old woman with metastatic donor-derived upper tract urothelial carcinoma (UTUC) discovered nine years postrenal transplant. Molecular diagnostic studies using polymerase chain reaction amplification of short tandem repeat alleles and HLA tissue typing proved that the urothelial carcinoma originated from donor tissue. She achieved sustained complete remission with transplant nephroureterectomy, retroperitoneal lymphadenectomy, immunosuppression withdrawal, and immunotherapy with pembrolizumab. Routine radiologic surveillance has demonstrated 15-month progression-free survival to date off pembrolizumab, and she is now under consideration for retransplantation. CONCLUSIONS: Immunotherapy using checkpoint inhibitors can serve as a novel treatment option for patients in the clinical predicament of having a solid organ transplant and simultaneous metastatic malignancy. In this report, we also discuss the oncogenic potential of BK virus, the use of checkpoint inhibitors in urothelial carcinoma, and the feasibility of retransplant for this patient population.
BACKGROUND: Donor-derived malignancy is a rare complication in patients who undergo organ transplant. Approaches to treatment have largely been individualized based on clinical circumstances given the lack of evidence-based guidelines, with therapeutic options ranging from discontinuation of immunosuppression and transplantectomy to the addition of chemotherapy or radiotherapy. Case Presentation. Herein, we describe a 60-year-old woman with metastatic donor-derived upper tract urothelial carcinoma (UTUC) discovered nine years postrenal transplant. Molecular diagnostic studies using polymerase chain reaction amplification of short tandem repeat alleles and HLA tissue typing proved that the urothelial carcinoma originated from donor tissue. She achieved sustained complete remission with transplant nephroureterectomy, retroperitoneal lymphadenectomy, immunosuppression withdrawal, and immunotherapy with pembrolizumab. Routine radiologic surveillance has demonstrated 15-month progression-free survival to date off pembrolizumab, and she is now under consideration for retransplantation. CONCLUSIONS: Immunotherapy using checkpoint inhibitors can serve as a novel treatment option for patients in the clinical predicament of having a solid organ transplant and simultaneous metastatic malignancy. In this report, we also discuss the oncogenic potential of BK virus, the use of checkpoint inhibitors in urothelial carcinoma, and the feasibility of retransplant for this patient population.
Authors: H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte Journal: J Clin Oncol Date: 2000-09 Impact factor: 44.544
Authors: H Myron Kauffman; Maureen A McBride; Wida S Cherikh; Pamela C Spain; William H Marks; Allan M Roza Journal: Transplantation Date: 2002-08-15 Impact factor: 4.939
Authors: Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic; Andrew E Grulich Journal: BMJ Date: 2010-02-11
Authors: Mohammed A Kaballo; Mark Canney; Patrick O'Kelly; Yvonne Williams; Conall M O'Seaghdha; Peter J Conlon Journal: Clin Kidney J Date: 2017-10-18
Authors: Noha Abdel-Wahab; Houssein Safa; Ala Abudayyeh; Daniel H Johnson; Van Anh Trinh; Chrystia M Zobniw; Heather Lin; Michael K Wong; Maen Abdelrahim; A Osama Gaber; Maria E Suarez-Almazor; Adi Diab Journal: J Immunother Cancer Date: 2019-04-16 Impact factor: 13.751